Andrew has extensive experience collaborating with clients across a diverse spectrum of strategic engagements involving asset-, disease-, and therapeutic area-level growth strategy, as well as pipeline and portfolio prioritization and strategy. He has worked across all major therapeutic areas, with recent focus in immunology, neurology, hematology, and vaccines. Andrew is committed to working closely with client teams in highly collaborative partnerships to drive to customized and actionable solutions to their most pressing clinical and commercial questions.
Andrew has 12+ years of experience in the life sciences space. Prior to joining ClearView, he received his Ph.D. in Biomedical Engineering from Columbia University where his research focused on predicting the functional consequences of traumatic brain injury. While at Columbia, Andrew was a Fellow at Columbia Technology Ventures where he assessed the commercial potential of early-stage innovation within the life sciences. Andrew previously received an MS in Biomedical Engineering from Columbia University and a BS in Biochemistry from the University of Iowa.
Debbi Amanti Belanger